Statement From Sequella Founder and CEO, Dr. Carol Nacy at the 'Stop TB' Meeting in Brazil on the Eve of Wo... ( RIO DE JANEIRO Brazil March 23 -- W...)

Statement From Sequella Founder and CEO, Dr. Carol Nacy at the 'Stop TB' Meeting in Brazil on the Eve of World TB Day

Date:3/23/2009

RIO DE JANEIRO, Brazil, March 23 /PRNewswire-USNewswire/ -- "With multidrug (MDR) and extremely drug (XDR) resistant tuberculosis on the rise, the world-wide financial crisis is of major concern to the international health community," said Dr. Carol Nacy, CEO of Sequella. "The Global Fund to fight HIV, malaria, and TB is running a huge deficit, and public health officials fear that any gains of the last 10 years in control of TB, especially in HIV-infected patients, will be lost. The specter of untreatable TB hangs like a pall over the STOP TB Partnership meeting in Rio de Janeiro, as patient advocates and health ministers, companies and non-governmental organizations, gather to determine how best to work together to even maintain the status quo."

About Sequella (www.sequella.com)

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for infectious diseases of epidemic potential. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

Sequella has both drugs and diagnostics in various stages of development. The company's lead drug candidate, SQ109 is a new diamine antibiotic intended to replace one or more of the current first-line anti-TB drugs and simplify patient therapy. SQ109 was granted U.S. FDA Fast Track designation and FDA/EMEA Orphan Drug Designation in 2007. SQ109 shows activity against drug sensitive and multi-drug resistant (MDR and XDR) Mycobacterium tuberculosis, the causative agent of TB. SQ109 is due to begin a Phase 1B study to assess safety and pharmacokinetics o
'/>"/>

0

GOOD

Page: 1 2
Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
5. Statement by Oscar S. Wyatt, Jr.
6. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
7. Pelosi Statement on Proposed Entitlement Task Force
8. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
9. Statement on House/Senate Agreement on SCHIP Legislation
10. Statement from the Alliance for Quality Nursing Home Care
11. Produce for Better Health Foundation Releases Statement on Study Saying Fruit & Vegetable Consumption Not Strongly Associated With Colon Cancer Risk

Post Your Comments:

Statement From Sequella Founder and CEO, Dr. Carol Nacy at the 'Stop TB' Meeting in Brazil on the Eve of Wo...( RIO DE JANEIRO Brazil March 23 -- W...),Health